NCT03248492 (Clinical Trial/ DS-8201a)

Study Title
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (NCT03248492)

Trial Description
Some HER-2 breast cancer patients do not respond or build resistance to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.

This trial is sponsored by Daiichi Sankyo Co., Ltd.®

Study Data

  • Condition: Breast Cancer
  • Interventions:
    • Drugs used in this trial
      • DS-8201a
  • Phase: II
  • Enrollment: 230
  • Start: August 2017
  • Estimated Completion: August 2019
  • Last verified: August 2017
  • Last Updated: August 2017

Study Schematic

Click here to Return to Drug map

Last Editorial review: August 30, 2017
Information based on (NIH/NCI) and other sources.